On January 5, 2024 Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, reported that it has signed an agreement with Janssen Research & Development, LLC (Janssen) (Press release, Illumina, JAN 5, 2024, View Source [SID1234639026]). This collaboration will be the first relating to the development of Illumina’s novel molecular residual disease (MRD) assay, a whole-genome sequencing (WGS) multi-cancer research solution that detects circulating tumor DNA (ctDNA) to better understand the persistence or recurrence of disease following clinical intervention.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
In oncology, MRD testing is increasingly being used as a prognostic indicator of disease recurrence after treatment by helping clinicians assess the effectiveness of a patient’s current course of clinical intervention and guide their decisions about precision therapy. MRD testing for solid tumors shows promise for improving the standard of care where current disease-monitoring tools fall short in accurately identifying patients’ response to treatment.
"This collaboration reflects the value of our unique MRD technology and the promise of Illumina’s whole-genome approach in oncology," said Joydeep Goswami, chief strategy and corporate development officer and chief financial officer of Illumina. "Working together with pharma partners like Janssen, we aim to deliver a sensitive, accurate, and easily accessible whole-genome sequencing MRD assay to advance clinical research in oncology."
The Illumina WGS MRD assay, which is currently in development, will detect ctDNA for MRD assessment in research settings that evaluate samples from patients previously diagnosed with cancer across multiple solid tumor indications. In contrast with existing MRD solutions with complex workflows, Illumina plans to develop a research solution that will provide a cost-effective, highly sensitive, and automated workflow, with the potential to achieve a turnaround time of five to seven days.
Illumina intends to collaborate with other leaders in pharma to help further develop and expand the utility of its WGS MRD assay.